ENDRA Life Sciences authorized shares increased from 20M to 1B; officer exculpation rejected

ENDRA Life Sciences Inc.

Authorized common shares increased from 20M to 1B via Certificate of Amendment effective Dec 10, 2025.
Stockholders rejected officer exculpation amendment (358,746 for, 63,603 against, 3,587 abstain).
Second Amendment to 2016 Omnibus Incentive Plan approved (406,837 for, 15,223 against).
Four director nominees elected with >418K votes each; RBSM LLP ratified as auditor (680,031 for).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ENDRA Life Sciences Inc.: Increased authorized common stock from 20,000,000 shares to 1,000,000,000 shares via Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation (effective 2025-12-10).

Change: charter amendment
Effective: 2025-12-10

Exact text from the filing

At the Annual Meeting, the Company’s stockholders approved and adopted a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of Company’s common stock, par value $0.0001 (the “Common Stock”), from 20,000,000 shares to 1,000,000,000 shares (the “Share Increase Amendment”). The Share Increase Amendment was filed with the Secretary of State of the State of Delaware on December 10, 2025 and was effective upon filing.

View on SEC.gov

268 governance changes filed in the last 30 days. Browse all governance changes →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-121374

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.